ORIC Pharmaceuticals, Inc.
ORIC
$8.60
-$0.23-2.61%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.18M | 8.70M | 7.90M | 8.52M | 8.08M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 39.62M | 34.55M | 36.67M | 39.06M | 32.72M |
| Operating Income | -39.62M | -34.55M | -36.67M | -39.06M | -32.72M |
| Income Before Tax | -35.77M | -30.51M | -32.59M | -36.36M | -30.02M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.77M | -30.51M | -32.59M | -36.36M | -30.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.77M | -30.51M | -32.59M | -36.36M | -30.02M |
| EBIT | -39.62M | -34.55M | -36.67M | -39.06M | -32.72M |
| EBITDA | -39.35M | -34.23M | -36.38M | -38.75M | -32.42M |
| EPS Basic | -0.34 | -0.30 | -0.33 | -0.47 | -0.42 |
| Normalized Basic EPS | -0.21 | -0.19 | -0.21 | -0.29 | -0.26 |
| EPS Diluted | -0.34 | -0.30 | -0.33 | -0.47 | -0.42 |
| Normalized Diluted EPS | -0.21 | -0.19 | -0.21 | -0.29 | -0.26 |
| Average Basic Shares Outstanding | 105.47M | 102.59M | 98.95M | 78.13M | 71.04M |
| Average Diluted Shares Outstanding | 105.47M | 102.59M | 98.95M | 78.13M | 71.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |